期刊
EUROSURVEILLANCE
卷 24, 期 3, 页码 18-22出版社
EUR CENTRE DIS PREVENTION & CONTROL
DOI: 10.2807/1560-7917.ES.2019.24.3.1800698
关键词
-
资金
- Ministry of Health, Labour and Welfare, Japan [10110400]
- JSPS KAKENHI [18K10036]
- Grants-in-Aid for Scientific Research [18K10036] Funding Source: KAKEN
The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据